<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361776</url>
  </required_header>
  <id_info>
    <org_study_id>2011/4-31/2</org_study_id>
    <nct_id>NCT01361776</nct_id>
  </id_info>
  <brief_title>Humoral Response to Tick-borne Encephalitis Vaccine in Elderly</brief_title>
  <official_title>Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sormland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sormland County Council, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibody titers after tick-borne encephalitis (TBE) vaccination are less in elderly and&#xD;
      vaccination breakthroughs are more common in this age group. This has prompted Swedish&#xD;
      authorities to recommend an additional dose in the initial vaccination schedule (= 0+30+90&#xD;
      days instead of the usually recommended 0+30 days. The investigators intend to evaluate this&#xD;
      regime.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risk for TBE increases in Sweden. Together with an increased awareness of the possibility&#xD;
      to acquire protection by vaccination, this has led to an increase in the number of doses of&#xD;
      the vaccine distributed in Sweden each year -now being approximately 400.000. The first year,&#xD;
      two doses with an interval of 1 month is recommended for the general population, followed by&#xD;
      a third dose approximately one year later and an additional booster dose three years after&#xD;
      the third.&#xD;
&#xD;
      Recent studies show that the antibody titers against TBE are substantially less in an older&#xD;
      population. This is in line with the present recommendation from Austria that booster&#xD;
      intervals should be shortened to 3 years in the age group 60+. It is also in line with a&#xD;
      report of vaccination failures where 13/27 patients were older than 60 years According to a&#xD;
      study by Jilkowa et al, 18 % (38/185) in the age group 60+ did not achieve putative levels of&#xD;
      antibody titers after the first two doses. Therefore, the manufacturer of Encepur recommends&#xD;
      a total of three doses to this age group using the same regimen as with &quot;accelerated&#xD;
      vaccination schedule (0+7+21 days). Unfortunately, GMT (geometrical mean of titers) after 3&#xD;
      doses with the accelerated schedule are not superior to 2 doses given at 0+30 days.&#xD;
&#xD;
      The manufacturer of FSME-immun instead recommends that serology should be checked one month&#xD;
      after the second dose and that a third dose should be given if titers are not sufficient&#xD;
      (0+30+60 days). Unfortunately, determinations of titers in a large number of samples put&#xD;
      severe strain on logistics and is not feasible in Sweden.&#xD;
&#xD;
      In order to try to improve immunity in the age group 60+ , the Department of Communicable&#xD;
      Disease Control and Prevention in Stockholm therefore recommends a third dose two months&#xD;
      after the first two doses to the age group 60+ (0+30+60 days).&#xD;
&#xD;
      Study design. The investigators intend to give FSME-immune to 3 groups with varying&#xD;
      vaccination schedules ( 0+7+21, 0+30 or 0+30+90. 50 participants will be randomized to each&#xD;
      group. Half of them will be between 50-59 years and half will be at least 60 years old. A&#xD;
      younger age group (50 participants between 18-49 years) will serve as controls and will be&#xD;
      given FSME-immune according to standard recommendations (0+30 days).&#xD;
&#xD;
      Serum samples (10 ml of blood) will be obtained at five times: 0,60,120,360 and 400 days&#xD;
      after first dose Samples will be analysed for neutralising antibodies at the Swedish&#xD;
      institute for Infectious disease control - other options possible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of neutralising antibodies against TBE one month after two or three doses.</measure>
    <time_frame>18 months after the first dose</time_frame>
    <description>Determination of neutralising antibodies one month after completion of the first years vaccination series</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of neutralising antibodies against TBE one month after the dose which will be given a year later</measure>
    <time_frame>18 months after the first dose has been given</time_frame>
    <description>Determination of neutralising antibodies one month after the dose which will be given a year later</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Tick-borne Encephalitis</condition>
  <arm_group>
    <arm_group_label>TBE vaccine at 0+30 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBE vaccine at 0+7+21 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBE vaccinte at 0+30+90 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>younger participants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FSME-immune</intervention_name>
    <description>0.5 ml im as scheduled in the 4 arms</description>
    <arm_group_label>TBE vaccine at 0+30 days</arm_group_label>
    <arm_group_label>TBE vaccine at 0+7+21 days</arm_group_label>
    <arm_group_label>TBE vaccinte at 0+30+90 days</arm_group_label>
    <arm_group_label>younger participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50 years or more&#xD;
&#xD;
          -  generally healthy&#xD;
&#xD;
          -  no immunosuppressive condition&#xD;
&#xD;
          -  fertile women must use contraceptives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous TBE infection&#xD;
&#xD;
          -  Previously immunized with TBE vaccine&#xD;
&#xD;
          -  Anaphylactic reaction to egg protein&#xD;
&#xD;
          -  Any disease or therapy which might suppress the immune response&#xD;
&#xD;
          -  Vaccination should be delayed if a participant has fever&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lars rombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Helsingfors</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Ã–rebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sormland County Council, Sweden</investigator_affiliation>
    <investigator_full_name>Lars Rombo</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>immune response</keyword>
  <keyword>TBE-vaccine</keyword>
  <keyword>elderly</keyword>
  <keyword>additional doses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

